LEVOCARNITINE SF: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novitium Pharma	LEVOCARNITINE SF	levocarnitine	SOLUTION;ORAL	211676	ANDA	ANI Pharmaceuticals, Inc.	70954-139-10	118 mL in 1 BOTTLE (70954-139-10)	2019-08-14
Novitium Pharma	LEVOCARNITINE SF	levocarnitine	SOLUTION;ORAL	211676	ANDA	ANI Pharmaceuticals, Inc.	70954-140-10	118 mL in 1 BOTTLE (70954-140-10)	2019-08-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

Levocarnitine SF (Sustained Formulation) is a formulation of L-carnitine, a naturally occurring amino acid derivative critical for fatty acid metabolism and energy production. In clinical applications, it's primarily administered to treat primary and secondary carnitine deficiencies, certain metabolic disorders, and cardiovascular conditions. As a specialty pharmaceutical, the procurement landscape for Levocarnitine SF is characterized by a blend of global and regional suppliers, each holding distinct roles in production, innovation, and distribution.

Market Overview

The global demand for levocarnitine and its formulations has steadily increased, driven by heightened awareness of metabolic disorders and expanded therapeutic indications. The pharmaceutical industry’s supply chain for Levocarnitine SF involves both active pharmaceutical ingredient (API) manufacturers and finished dosage form (FDF) producers, often operating under strict quality controls and regulatory approvals.

Leading Suppliers of Levocarnitine SF

The primary suppliers are distinguished by their manufacturing capacity, compliance with international standards (such as cGMP and ISO certifications), and geographic reach. Although many companies produce L-carnitine APIs, only select firms manufacture and supply the sustained formulation variants suitable for clinical and hospital use.

1. Sage Therapeutics

Overview: Sage Therapeutics is a key player in L-carnitine API manufacturing, with facilities approved by major regulatory authorities.
Supply Focus: They supply high-purity L-carnitine APIs, which are used by pharmaceutical companies to develop sustained-release formulations.
Strengths: Proven track record in pharmaceutical manufacturing, reliable supply chain, and competitive pricing.

2. Novelists Inc. (Shandong Lijian Pharmaceutical Co., Ltd.)

Overview: Based in China, this company specializes in bulk API production, including L-carnitine.
Supply Focus: Extensive capacity for L-carnitine API with certifications suitable for export.
Strengths: Cost-effective manufacturing with global distribution capabilities.

3. Zhejiang Medicine Co., Ltd.

Overview: A major Chinese pharmaceutical company producing L-carnitine APIs.
Supply Focus: Supplies APIs used in both generic and branded levocarnitine formulations, including sustained-release variants.
Strengths: Integrated manufacturing process, large volume production, adheres to international quality standards.

4. Jiangsu Hengrui Medicine Co., Ltd.

Overview: A leading Chinese pharmaceutical enterprise with capabilities in amino acid derivatives.
Supply Focus: API production for L-carnitine, with ongoing R&D for formulation innovations.
Strengths: Strong R&D pipeline, extensive distribution network.

5. Teva Pharmaceutical Industries Ltd.

Overview: A global generic pharmaceuticals manufacturer that produces finished dosage forms, including levocarnitine formulations.
Supply Focus: Assembles and distributes Levocarnitine SF in various markets, often through licensed partnerships.
Strengths: Extensive international footprint, regulatory expertise.

Alternative and Regional Suppliers

Apart from top-tier manufacturers, regional suppliers—particularly in India and Southeast Asia—contribute significantly to the supply chain through local API production and FDF manufacturing, fulfilling regional market demands.

Regulatory and Quality Considerations

Suppliers must comply with stringent standards, including:

cGMP (Current Good Manufacturing Practices): Ensures consistent quality and safety.
ISO Certifications: Particularly ISO 9001 for quality management systems.
Regulatory Approvals: Mandated by agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and China's CFDA.

Emerging Supply Trends

Vertical Integration: Manufacturers increasingly control both API and formulation production to optimize quality and supply stability.
Contract Manufacturing: Pharma companies often source from Contract Development and Manufacturing Organizations (CDMOs) with proven expertise.
Supply Chain Diversification: To mitigate risks related to geopolitical issues, suppliers are diversifying sources across different regions.

Future Outlook

The future of Levocarnitine SF suppliers hinges on technological innovation in sustained-release formulations, regulatory approvals for new markets, and supply chain resilience. Companies investing in advanced R&D and maintaining compliance are better positioned to capitalize on market growth.

Key Takeaways

The global supply chain for Levocarnitine SF is dominated by reputable API manufacturers in China, India, and Europe, with key players including Sage Therapeutics, Zhejiang Medicine, and Jiangsu Hengrui.
Regulatory compliance, high-quality manufacturing, and diversified supply sources are critical for consistent availability.
Regional suppliers play significant roles, especially in emerging markets, with cost-effective production but often require strict quality verification.
The shift towards integrated manufacturing and contract partnerships offers stability and innovation advantages.
Monitoring regulatory developments and technological trends is essential for positioning within this specialized market.

FAQs

1. Who are the main global API producers of L-carnitine used in Levocarnitine SF?
Major API producers include Zhejiang Medicine, Jiangsu Hengrui, and Sage Therapeutics, all with robust manufacturing capacities and quality certifications suitable for pharmaceutical-grade products.

2. Can regional suppliers reliably supply Levocarnitine SF in global markets?
Yes, regional suppliers in China and India are key contributors; however, buyers must ensure they meet international quality standards and regulatory approvals for global distribution.

3. What should pharmaceutical companies consider when sourcing Levocarnitine SF?
Quality certification (cGMP, ISO), regulatory compliance, supply capacity, price competitiveness, and the supplier’s track record are critical factors.

4. Are there innovations in Levocarnitine SF formulations expected in the near future?
Yes, ongoing research aims to develop improved sustained-release formulations that enhance bioavailability and patient compliance.

5. How is supply chain risk managed for Levocarnitine SF?
Diversification across multiple suppliers, strategic stockpiling, and ensuring compliance with regulatory standards are common practices to mitigate risks.

References

[1] Global Pharmaceutical API Market Report, 2022.
[2] "L-Carnitine Production and Market Trends," Journal of Pharmaceutical Development, 2021.
[3] Chinese Pharmaceutical Industry Overview, 2022.
[4] US FDA Approved API Manufacturers, 2023.
[5] Emerging Trends in Sustained Release Formulations, Pharmaceutical Tech Review, 2022.

Suppliers and packagers for LEVOCARNITINE SF